for prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction or when administered (in conjunction with warfarin) as inpatient treatment of acute DVT with or ...

Purpose: The current indications, dosing, and practical considerations for use of newer anticoagulants in patients with various degrees of renal impairment who do not require dialysis are reviewed.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

such as the direct oral anticoagulants, but also because of the development of new clinical and therapeutic indications, which go beyond the classical prevention of cardioembolism in atrial ...

"Associations between dose of anticoagulation and outcome appeared broadly consistent across all predefined patient subgroups ...

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

FRIDAY, Dec. 6, 2024 (HealthDay News) -- Noninferiority of reduced- versus full-dose anticoagulants cannot be proven in ...

For people taking blood thinners after experiencing a blood clot, a new study suggests that reducing the dose after six ...

Anticoagulation with apixaban or rivaroxaban may be used to reduce thromboembolism risk, but be wary of fracture risk.

A Korea Institute of Science and Technology (KIST) research team has developed a novel stent surface treatment technology ...

2024 — More than two-thirds of people taking blood thinners take direct oral anticoagulants, or DOACs, which are under- or over-prescribed in up to one in eight patients. A new study finds that most ...